Pulsed electric field therapy for advanced lung cancer after immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment called pulsed electric field therapy for people with advanced lung cancer (stage III or IV) that has not responded to first-line immunotherapy. It uses targeted electrical pulses to destroy tumor cells, and may be an option for those who still have other measurable tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 22 years or older with advanced non-small cell lung cancer (stage III or IV).
- You have already tried anti-PD-1 immunotherapy as your first treatment, and the cancer continued to grow.
- The tumor that will be treated with pulsed electric fields is 3 cm or smaller (or up to 5 cm if multiple treatments can be given in one session).
- You have at least one other measurable tumor besides the one being treated.
- You are in generally good health (able to do light activities) and have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses short electrical pulses (pulsed electric field ablation) to destroy small lung tumors. It may be an option for people with limited, early-stage non-small cell lung cancer who can tolerate a minimally invasive procedure.
This trial tests a device that sends low-energy electrical fields (called Tumor Treating Fields) to the lung tumor before surgery. The goal is to see if it can help shrink the tumor and improve surgical outcomes.
This study tests a new device that uses brief electrical pulses (pulsed electric field or PEF) to treat lung tumors before they are surgically removed. The goal is to see if this approach can be safely added to standard lung cancer surgery.
This study tests whether adding electro-acupuncture (a gentle type of acupuncture with mild electrical pulses) to standard first-line immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer. It aims to see if this combination improves quality of life and overall treatment outcomes.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This trial tests a new treatment called pulsed electric field (PEF) therapy for people with advanced or unresectable esophageal squamous cell carcinoma. PEF uses short electrical pulses to target and destroy cancer cells. This study is for patients who cannot have surgery or standard treatments, and looks at how safe and effective this therapy is.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.